SOLID TUMORS
Clinical trials for SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new SOLID TUMORS trials appear
Sign up with your email to follow new studies for SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo targets hard-to-treat BRAF cancers in early trial
Disease control CompletedThis early-phase study tested a new drug called CFT1946, alone or combined with trametinib or cetuximab, in 89 adults with advanced solid tumors that have a BRAF V600 mutation (including melanoma, lung, colon, and thyroid cancers). The main goals were to check safety and find the…
Matched conditions: SOLID TUMORS
Phase: PHASE1 • Sponsor: C4 Therapeutics, Inc. • Aim: Disease control
Last updated May 01, 2026 15:26 UTC
-
Experimental drug TdCyd tested in advanced cancer patients
Disease control CompletedThis early-phase trial tested a new drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see how the drug affects the body. TdCyd aims to reactivate genes that slow tumor growth, potenti…
Matched conditions: SOLID TUMORS
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 01, 2026 15:24 UTC
-
New drug shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called FF-10502-01 in 106 people with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drug could shrink tumors or slow disease progression. The study is now com…
Matched conditions: SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
New drug combo shows promise against tough cancers
Disease control CompletedThis early-phase study tested a new drug called eciskafusp alfa (RO7284755), alone or with another immunotherapy (atezolizumab), in 189 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dos…
Matched conditions: SOLID TUMORS
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC
-
New drug combo shows promise in advanced cancers
Disease control CompletedThis early-phase study tested a new experimental drug called DF6002, given alone or with the immunotherapy nivolumab, in 170 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if …
Matched conditions: SOLID TUMORS
Phase: PHASE1 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC
-
Tumor testing study helps match patients to the right clinical trial
Knowledge-focused CompletedThis study tested tumor tissue samples from 470 people with solid tumors to look for specific biomarkers. The goal was to see if those biomarkers made them eligible for other Roche clinical trials testing new treatments. Participants did not receive any treatment as part of this …
Matched conditions: SOLID TUMORS
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated May 01, 2026 15:24 UTC
-
Home immunotherapy: do patients like it?
Knowledge-focused CompletedThis study in France looked at how satisfied cancer patients were when they switched from getting immunotherapy in the hospital to getting it at home. 49 adults with solid tumors took part. The goal was to see if home treatment improved their care experience.
Matched conditions: SOLID TUMORS
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated May 01, 2026 15:24 UTC
-
Gene-Based drug study aims to personalize cancer treatment
Knowledge-focused CompletedThis early-phase study looked at how the cancer drug belinostat is processed in the body and its safety in 17 patients with advanced solid tumors or blood cancers. Participants were grouped by their UGT1A1 gene type (common or variant) to see if genetic differences affect drug br…
Matched conditions: SOLID TUMORS
Phase: PHASE1 • Sponsor: Acrotech Biopharma Inc. • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:51 UTC